S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Zai Lab Stock Forecast, Price & News

-4.17 (-10.07%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
597,149 shs
Average Volume
773,698 shs
Market Capitalization
$3.65 billion
P/E Ratio
Dividend Yield
Price Target

Zai Lab MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
215.5% Upside
$117.50 Price Target
Short Interest
3.08% of Shares Sold Short
Dividend Strength
News Sentiment
0.33mentions of Zai Lab in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($4.18) to ($2.92) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.79 out of 5 stars

Medical Sector

713th out of 1,433 stocks

Pharmaceutical Preparations Industry

355th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock News Headlines

Zai Lab Stock Has Fallen to Value Levels
Commercial stage global biotech company Zai Lab (NASDAQ: ZLAB) stock has cratered (-82%) from a 52-week high of $178.91.
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $23.14
Expert Ratings for Zai Lab
Zai Lab Earnings, Revenue Beat in Q1
Zai Lab Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$144.31 million
Book Value
$14.31 per share


Free Float
Market Cap
$3.65 billion

Zai Lab Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2022?

5 Wall Street analysts have issued 1 year price objectives for Zai Lab's shares. Their ZLAB stock forecasts range from $64.00 to $193.00. On average, they expect Zai Lab's share price to reach $117.50 in the next twelve months. This suggests a possible upside of 215.5% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

How has Zai Lab's stock performed in 2022?

Zai Lab's stock was trading at $62.85 at the start of the year. Since then, ZLAB stock has decreased by 40.7% and is now trading at $37.24.
View the best growth stocks for 2022 here

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Zai Lab

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.23. The firm had revenue of $43.10 million for the quarter, compared to analysts' expectations of $42.43 million. Zai Lab had a negative net margin of 324.08% and a negative trailing twelve-month return on equity of 37.26%.
View Zai Lab's earnings history

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab updated its first quarter earnings guidance on Tuesday, May, 10th. The company provided earnings per share (EPS) guidance of ($0.86) for the period, compared to the consensus EPS estimate of ($1.23). The company issued revenue guidance of $46.7 million, compared to the consensus revenue estimate of $45.72 million.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Dr. Ying Du Ph.D., Founder, Chairperson & CEO (Age 56, Pay $1.64M)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 44, Pay $720.97k)
  • Mr. Frazor Titus Edmondson III, Chief Legal Officer & Corp. Sec. (Age 56, Pay $829k)
  • Dr. Harald Reinhart M.D., Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases (Age 70, Pay $845.94k) (LinkedIn Profile)
  • Dr. Alan Bart Sandler M.D., Pres & Head of Global Devel. in Oncology (Age 65, Pay $1.19M)
  • Ms. Ann Beasley, Chief Compliance Officer
  • Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 57)
  • Dr. Jonathan J. Wang M.B.A., MBA, Ph.D., Exec. VP & Head of Bus. Devel. (Age 40)
  • Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 58)
  • Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 51)

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $37.24.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.65 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 1,951 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for Zai Lab is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.